SCHEMBL21797145

SCHEMBL21797145

O=C(O)C1CN(c2cc(Cl)ncn2)CCO1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 1/20 0.44
MAP4K4 O95819 1/20 0.38
EIF2AK4 Q9P2K8 1/20 0.37
PIK3CA P42336 1/20 0.37
ELOVL1 Q9BW60 1/20 0.37
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 1/20 0.37
ATM Q13315 1/20 0.37
PDK1 Q15118 1/20 0.37
HSD11B1 P28845 1/20 0.37
EGFR P00533 1/20 0.36
ERBB3 P21860 1/20 0.36
OGA O60502 1/20 0.34
P4HTM Q9NXG6 1/20 0.34
USP30 Q70CQ3 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
HTT P42858 1/20 0.34
PRCP P42785 2/20 0.34
FPR2 P25090 1/20 0.34
SCN9A Q15858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28607925 1.00 KMO (0.44) KMOMAP4K4EIF2AK4PIK3CAELOVL1
Formamide SCHEMBL28601016 0.94 KMO (0.40) KMOMAP4K4EIF2AK4PIK3CAELOVL1
SCHEMBL21796661 0.85 GRIN2B (0.43) MAP4K4USP30PIK3CD
SCHEMBL21796840 0.85 GRIN2B (0.43) MAP4K4USP30PIK3CD
SCHEMBL22873464 0.85 SCN9A (0.42) KMOMAP4K4EIF2AK4ELOVL1NPC1
SCHEMBL18399166 0.85 GRIN2B (0.43) MAP4K4USP30PIK3CD
SCHEMBL20899406 0.85 SCN9A (0.42) KMOMAP4K4EIF2AK4ELOVL1NPC1
SCHEMBL20899405 0.85 SCN9A (0.42) KMOMAP4K4EIF2AK4ELOVL1NPC1
SCHEMBL28601014 0.81 MAP4K4 (0.35) KMOMAP4K4EIF2AK4ELOVL1NPC1
SCHEMBL23525831 0.78 LRRK2 (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108137510-B Compound (I) 葛兰素史密斯克莱知识产权发展有限公司 2021-07-20 CN disclosed
US-10975081-B2 Substituted fused pyrazole compounds and their use as LRRK2 inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-04-13 US disclosed
EP-3325449-B1 HETEROCYCLIC COMPOUNDS, PARTICULARLY PYRIMIDINYLINDAZOLE COMPOUNDS FOR TREATING PARKINSON'S DISEASE GLAXOSMITHKLINE IP DEV LTD (GB) 2021-01-13 EP disclosed
US-20200079777-A1 COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10975081-B2 Substituted fused pyrazole compounds and their use as LRRK2 inhibitors LRRK2, PARK7, PINK1 KMO 913/4885MAP4K4 195/4885EIF2AK4 365/4885
US-20200079777-A1 COMPOUNDS LRRK2, PARK7, PINK1 KMO 2087/4885MAP4K4 289/4885EIF2AK4 458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.